Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

1.

Long-term efficacy and tolerability of abdominal once-yearly histrelin acetate subcutaneous implants in patients with advanced prostate cancer.

Woolen S, Holzmeyer C, Nesbitt E, Siami PF.

Prostate Cancer. 2014;2014:490315. doi: 10.1155/2014/490315. Epub 2014 Dec 4.

PMID:
25548680
[PubMed]
Free PMC Article
2.

Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study.

Lebret T, Davin JL, Hennequin C, Latorzeff I, Mignard JP, Moreau JL, Rossi D, Ruffion A, Zerbib M, Culine S.

Ther Adv Urol. 2014 Dec;6(6):205-14. doi: 10.1177/1756287214542418.

PMID:
25435914
[PubMed]
Free PMC Article
3.

Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Alkhateeb S, Abusamra A, Rabah D, Alotaibi M, Mahmood R, Almansour M, Murshid E, Alsharm A, Alolayan A, Ahmad I, Alkushi H, Alghamdi A, Bazarbashi S.

Urol Ann. 2014 Oct;6(4):278-85. doi: 10.4103/0974-7796.140959.

PMID:
25371601
[PubMed]
Free PMC Article
4.

SEOM clinical guidelines for the treatment of metastatic prostate cancer.

Cassinello J, Climent MA, González del Alba A, Mellado B, Virizuela JA.

Clin Transl Oncol. 2014 Dec;16(12):1060-6. doi: 10.1007/s12094-014-1225-3. Epub 2014 Oct 16.

PMID:
25319721
[PubMed - in process]
Free PMC Article
5.

Predictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapy.

Chen CH, Hsieh JT, Huang KH, Pu YS, Chang HC.

PLoS One. 2014 Aug 14;9(8):e105091. doi: 10.1371/journal.pone.0105091. eCollection 2014.

PMID:
25121948
[PubMed - in process]
Free PMC Article
6.

Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.

Kahn B, Collazo J, Kyprianou N.

Int J Biol Sci. 2014 Jun 1;10(6):588-95. doi: 10.7150/ijbs.8671. eCollection 2014.

PMID:
24948871
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Geriatric considerations in the treatment of advanced prostate cancer.

Kessler ER, Flaig TW.

F1000Prime Rep. 2014 May 6;6:33. doi: 10.12703/P6-33. eCollection 2014. Review.

PMID:
24860655
[PubMed]
Free PMC Article
8.

Novel agents in the management of castration resistant prostate cancer.

Chaturvedi S, Garcia JA.

J Carcinog. 2014 Mar 5;13:5. doi: 10.4103/1477-3163.128185. eCollection 2014. Review.

PMID:
24799832
[PubMed]
Free PMC Article
9.

The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making.

Van den Broeck T, Joniau S, Clinckemalie L, Helsen C, Prekovic S, Spans L, Tosco L, Van Poppel H, Claessens F.

Biomed Res Int. 2014;2014:627510. doi: 10.1155/2014/627510. Epub 2014 Feb 19. Review.

PMID:
24701578
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.

Wex J, Sidhu M, Odeyemi I, Abou-Setta AM, Retsa P, Tombal B.

Clinicoecon Outcomes Res. 2013 Jun 24;5:257-69. doi: 10.2147/CEOR.S44855. Print 2013.

PMID:
23836996
[PubMed]
Free PMC Article
11.

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.

Tunn UW, Gruca D, Bacher P.

Clin Interv Aging. 2013;8:457-64. doi: 10.2147/CIA.S27931. Epub 2013 Apr 26. Review.

PMID:
23637525
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Endocrine manipulations in cancer prostate: A review.

Rajput R, Sehgal A.

Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S199-204. doi: 10.4103/2230-8210.104039.

PMID:
23565378
[PubMed]
Free PMC Article
13.

Novel therapies for the treatment of advanced prostate cancer.

Clarke JM, Armstrong AJ.

Curr Treat Options Oncol. 2013 Mar;14(1):109-26. doi: 10.1007/s11864-012-0222-4. Review.

PMID:
23322116
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Current management of prostate cancer: dilemmas and trials.

O'Hanlon Brown C, Waxman J.

Br J Radiol. 2012 Nov;85 Spec No 1:S28-40. doi: 10.1259/bjr/13017671.

PMID:
23118100
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis.

Tunio MA, Al-Asiri M, Al-Amro A, Bayoumi Y, Fareed M.

Curr Oncol. 2012 Aug;19(4):e280-8. doi: 10.3747/co.19.993.

PMID:
22876157
[PubMed]
Free PMC Article
17.

Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.

Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, Eddy S, Shih W, DiPaola RS.

Med Sci Monit. 2012 Apr;18(4):CR260-4.

PMID:
22460098
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

Connolly RM, Carducci MA, Antonarakis ES.

Asian J Androl. 2012 Mar;14(2):177-86. doi: 10.1038/aja.2011.103. Epub 2012 Jan 9. Review.

PMID:
22231299
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer.

Godbole AM, Njar VC.

Prostate Cancer. 2011;2011:918707. doi: 10.1155/2011/918707. Epub 2011 Oct 12.

PMID:
22111003
[PubMed]
Free PMC Article
20.

Mathematical modeling of prostate cancer progression in response to androgen ablation therapy.

Jain HV, Clinton SK, Bhinder A, Friedman A.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19701-6. doi: 10.1073/pnas.1115750108. Epub 2011 Nov 21.

PMID:
22106268
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk